Novartis: Q2 3%/12% beat on Sales/EPS, mostly OpEx control, but FY26 LC guide only reit. See only slight cons U/Gs and shareprice outperf.

Research evidence excerpt

Novartis: Q2 3%/12% beat on Sales/EPS, mostly OpEx control, but FY26 LC guide only reit. See only slight cons U/Gs and shareprice outperf.

Barclays | Novartis

communication should not rely on or act upon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the

Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

European Economic Area (“EEA”): This material is being distributed to any “Authorised User” located in a Restricted EEA Country by Barclays Bank

Ireland PLC. The Restricted EEA Countries are Austria, Bulgaria, Estonia, Finland, Hungary, Iceland, Liechtenstein, Lithuania, Luxembourg, Malta,

Portugal, Romania, Slovakia and Slovenia. For any other “Authorised User” located in a country of the European Economic Area, this material is being

distributed by Barclays Bank PLC. Barclays Bank Ireland PLC is a bank authorised by the Central Bank of Ireland whose registered office is at 1

Molesworth Street, Dublin 2, Ireland. Barclays Bank PLC is not registered in France with the Autorité des marchés financiers or the Autorité de contrôle

prudentiel. Authorised User means each individual associated with the Client who is notified by the Client to Barclays and authorised to use the

Research Services. The Restricted EEA Countries will be amended if required.

Finland: Notwithstanding Finland’s status as a Restricted EEA Country, Research Services may also be provided by Barclays Bank PLC where permitted

by the terms of its cross-border license.

Americas: The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital

Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S.